Significant childhood cancer discovery made by scientists at the BC Cancer Agency

Vancouver B.C. – Research published today by scientists at the BC Cancer Agency in Cancer Cell brings new hope for the treatment of high-risk childhood sarcomas – a type of cancer that has seen almost no treatment improvement in the last 20 years in spite of intense research efforts. Sarcomas are malignant – meaning they are cancerous – tumors of the connective tissues, including bones and...

Lifetime vigorous physical activity may lower risk of non-Hodgkin Lymphoma

A study from the Agency’s Center for Lymphoid Cancer shows that performing vigorous physical activity over your lifetime may lower your risk of non-Hodgkin lymphoma (NHL). The case-control study found that the most physically active participants had a lower risk for NHL than the least active participants, and that vigorous physical activity in particular was the most effective at lowering this...

BC Cancer Agency’s POG Program leads to a unique breakthrough in a patient’s treatment

Vancouver, B.C. – The Personalized Onco-Genomics (POG) Program at the BC Cancer Agency has identified a life-altering treatment option for a patient with advanced cancer. POG has given Trish Keating a new reason to hope as the genomic sequencing of her aggressive colorectal cancer identified a unique protein function at play. This critical detail pointed to an outside-of-the-box treatment option...

BC Cancer Foundation raises $6.5 million to secure first-in-Canada treatment technology at the BC Cancer Agency

Vancouver, BC – The BC Cancer Foundation has reached its $6.5-million fundraising target to purchase a state-of-the-art Vero™ machine to benefit cancer patients across B.C. The technologically-advanced radiotherapy system will be the first machine of its kind in Canada, as renovations get underway to accommodate the new treatment delivery system at the BC Cancer Agency Vancouver Centre. “We are...

BC Cancer Agency Researchers Co-Lead $60 Million National Initiative for Innovative Cancer Treatments

VANCOUVER – BC Cancer Agency researchers will play a key role in the first Network of Centres of Excellence (NCE) devoted to cancer research, announced today with a $25 million commitment from the Government of Canada and an additional $35 million from partners across the country. The NCE, called BioCanRX, will focus on the development of new biotherapeutics – therapies derived from biological...

BC Cancer Agency lay the foundation for clinical trials involving "adoptive T cell therapy"

Dr. Brad Nelson, Director of the BC Cancer Agency’s Trev & Joyce Deeley Research Centre in Victoria, and his team lay the foundation for clinical trials involving a form of immunotherapy called “adoptive T cell therapy” or ACT. Groundbreaking cancer research has advanced from a concept to compelling scientific proof that enhancing the body’s natural immune response to cancer through ACT can...

BC Cancer Agency scientists make internationally significant discovery, mapping the evolution of breast cancer ‘avatars’

Vancouver – A just-published paper in the prestigious journal Nature highlights how researchers at the BC Cancer Agency are using human breast cancer ‘avatars’ — models of human breast cancers — to measure how complex cancers develop and change over time. The research is unprecedented because it uses single cancer cells to expose how breast cancers evolve and how to identify the cell populations...

Personalized Onco-Genomics sets a global precedent

The Personalized Onco-Genomics (POG) Program sets a global precedent both in terms of the diversity of cancers investigated and the number of patients participating. The 2014 Inspiration Gala raised $5 million to support part II of POG, seeing more than 300 patients enter a world-first clinical study that provides oncologists with gamechanging genomic data to guide treatment decisions. POG is a...

The BC Cancer Agency’s Genito-Urinary tumour group and Radiotherapy Program approve and implement HDR brachytherapy “boost”

The BC Cancer Agency’s Genito-Urinary tumour group and Radiotherapy Program approve and implement HDR brachytherapy “boost” (implanted radiation in addition to standard external beam radiation) as standard treatment for patients with both high-tier intermediate and high-risk prostate cancer, meaning this evolutionary treatment improvement will benefit patients who need it most. HDR brachytherapy...

Pages